| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KU-55933 | GDSC1000 | pan-cancer | AAC | 0.038 | 0.4 |
| mRNA | SGC0946 | GDSC1000 | pan-cancer | AAC | -0.038 | 0.4 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | -0.043 | 0.4 |
| mRNA | JQ-1 | GDSC1000 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | -0.038 | 0.4 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.037 | 0.4 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.064 | 0.4 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.047 | 0.4 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | 0.057 | 0.4 |